Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Venous Thrombosis

  Free Subscription


Articles published in Circulation

Retrieve available abstracts of 19 articles:
HTML format



Single Articles


    November 2021
  1. NAEIJE R
    Letter by Naeije Regarding Article, "Oxygen Pathway Limitations in Patients With Chronic Thromboembolic Pulmonary Hypertension".
    Circulation. 2021;144:e328-e329.
    PubMed    


  2. HOWDEN EJ, Ruiz-Carmona S, La Gerche A, Delcroix M, et al
    Response by Howden et al to Letter Regarding Article, "Oxygen Pathway Limitations in Patients With Chronic Thromboembolic Pulmonary Hypertension".
    Circulation. 2021;144:e330-e331.
    PubMed    


    May 2021
  3. ROBERT-EBADI H, Robin P, Hugli O, Verschuren F, et al
    Impact of the Age-Adjusted D-Dimer Cutoff to Exclude Pulmonary Embolism: A Multinational Prospective Real-Life Study (the RELAX-PE Study).
    Circulation. 2021;143:1828-1830.
    PubMed    


    April 2021
  4. HOWDEN EJ, Ruiz-Carmona S, Claeys M, de Bosscher R, et al
    Oxygen Pathway Limitations in Patients with Chronic Thromboembolic Pulmonary Hypertension.
    Circulation. 2021 Apr 15. doi: 10.1161/CIRCULATIONAHA.120.052899.
    PubMed     Abstract available


    March 2021
  5. BUKHARI S, Barakat AF, Eisele YS, Nieves R, et al
    Prevalence of Atrial Fibrillation and Thromboembolic Risk in Wild-Type Transthyretin Amyloid Cardiomyopathy.
    Circulation. 2021;143:1335-1337.
    PubMed    


    February 2021

  6. Correction to: Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients: A Policy Statement From the American Heart Association.
    Circulation. 2021;143:e249.
    PubMed    


    November 2020
  7. PACKARD CJ
    Letter by Packard Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Tr
    Circulation. 2020;142:e333-e334.
    PubMed    


  8. SCHWARTZ GG, Szarek M, Bittner VA, Steg PG, et al
    Response by Schwartz et al to Letter Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Ran
    Circulation. 2020;142:e335-e336.
    PubMed    


    October 2020
  9. MARSTON NA, Ruff CT, Sabatine MS
    Response by Marston et al to Letter Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism".
    Circulation. 2020;142:e264.
    PubMed    


  10. QI Z, Sun A, Ge J
    Letter by Qi et al Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism".
    Circulation. 2020;142:e262-e263.
    PubMed    


    August 2020
  11. CUSHMAN M, Barnes GD, Creager MA, Diaz JA, et al
    Venous Thromboembolism Research Priorities: A Scientific Statement From the American Heart Association and the International Society on Thrombosis and Haemostasis.
    Circulation. 2020;142:e85-e94.
    PubMed     Abstract available


    July 2020
  12. SPYROPOULOS AC, Weitz JI
    Hospitalized COVID-19 Patients and Venous Thromboembolism: A Perfect Storm.
    Circulation. 2020;142:129-132.
    PubMed    


    June 2020

  13. Correction to: Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients: A Policy Statement From the American Heart Association.
    Circulation. 2020;141:e932.
    PubMed    


    May 2020
  14. HENKE PK, Kahn SR, Pannucci CJ, Secemksy EA, et al
    Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients: A Policy Statement From the American Heart Association.
    Circulation. 2020 May 7:CIR0000000000000769. doi: 10.1161/CIR.0000000000000769.
    PubMed     Abstract available


    April 2020
  15. POISSY J, Goutay J, Caplan M, Parmentier E, et al
    Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence.
    Circulation. 2020 Apr 24. doi: 10.1161/CIRCULATIONAHA.120.047430.
    PubMed    


    March 2020
  16. SCHWARTZ GG, Steg PG, Szarek M, Bittner VA, et al
    Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of a Randomized Clinical Trial.
    Circulation. 2020 Mar 29. doi: 10.1161/CIRCULATIONAHA.120.046524.
    PubMed     Abstract available


  17. MARSTON NA, Gurmu Y, Melloni GEM, Bonaca M, et al
    The Effect of PCSK9 Inhibition on the Risk of Venous Thromboembolism.
    Circulation. 2020 Mar 29. doi: 10.1161/CIRCULATIONAHA.120.046397.
    PubMed     Abstract available


    January 2020
  18. GERGES C, Gerges M, Friewald R, Fesler P, et al
    Microvascular Disease in Chronic Thromboembolic Pulmonary Hypertension: Hemodynamic Phenotyping and Histomorphometric Assessment.
    Circulation. 2020 Jan 3. doi: 10.1161/CIRCULATIONAHA.119.041515.
    PubMed     Abstract available


    October 2019
  19. GIRI J, Sista AK, Weinberg I, Kearon C, et al
    Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association.
    Circulation. 2019 Oct 4:CIR0000000000000707. doi: 10.1161/CIR.0000000000000707.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Venous Thrombosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: